- Products & Services
- Science & Technology
Ultra-sensitive next-generation sequencing for the reliable detection of rare mutant molecules through optimized technology and panel design
SafeSEQ technology delivers best-in-class, ultra-sensitive NGS liquid biopsy solutions to identify tumor mutations across cancer types for a range of intended uses, including to better-inform therapy selection, dynamically monitor tumor response, identify molecular mediators of resistance, and detect minimal residual disease at a variant level that is an order of magnitude more sensitive than other methods.
Every clinical development program is unique, and molecular testing needs are not always readily apparent. Clinical NGS-based testing is a balance of sample input DNA amount and sequencing cost. As a result, a trade-off exists between sensitivity and genomic coverage.
Coverage across a large area is possible at relatively low sensitivity, or high sensitivity can be achieved for a focused range of clinically relevant targets. Large, fixed NGS panels can cover a significant number of markers. Unfortunately, this limits sensitivity and wastes sequencing power on regions that do not yield useful information for your therapy.
Innate workflow optimizations and conservation of input DNA molecules ensure SafeSEQ's ultra-sensitive and efficient detection of ctDNA for clinically relevant targets, unlike pan-cancer NGS panels, which sacrifice sensitivity for broad coverage.
SafeSEQ's best-in-class sensitivity for detecting ctDNA can expedite and improve advanced therapeutic clinical development programs by accurately identifying ctDNA across a range of tumor types.
The UIDs enable discrimination of real mutations from errors that may be introduced by technologies during the amplification and sequencing process.